Phase II to Phase III Study, Double Blind, Placebo Controlled of Duloxetine to Prevent Oxaliplatin Induced Chemotherapy Induced Peripheral Neuropathy

February 18, 2021

Protocol: Alliance – A221805

SCHEMA A221805

Please Note: Below is partial eligibility, for full eligibility requirements, please contact GHCI Research Department at (810)762-8181, (810)762-8079 and or (810)762-8038. Thank you!

Eligibility:

  1. Stage II-III colorectal cancer patients scheduled to receive treatment.
  2. No prior neurotoxic chemotherapy.
  3. No pre-existing clinical or pre-clinical peripheral neuropathy from any cause.
  4. At least 25 years of age.
  5. ECOG Performance Status 0-2

Genesys Hurley Cancer Institute

302 Kensington Avenue (Print a Map)
Flint, MI 48503

810-762-8226 | 888-762-8675

Ascension Genesys Hospital
Hurley Medical Center
Michigan Cancer Consortium

Newsletter

Ⓒ 2020 Genesys Hurley Cancer Institute | All Rights Reserved.